Published in J Virol on January 02, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res (2013) 0.91
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther (2013) 0.90
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. J Virol (2014) 0.80
Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol (2013) 0.80
Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. Cancer Gene Ther (2013) 0.79
Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex. Sci Rep (2016) 0.76
Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer. J Virol (2015) 0.75
Recombinant mumps virus as a cancer therapeutic agent. Mol Ther Oncolytics (2016) 0.75
Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. Mol Ther Oncolytics (2015) 0.75
VSV based virotherapy in ovarian cancer: the past, the present and …future? J Cancer (2017) 0.75
The scanning model for translation: an update. J Cell Biol (1989) 31.23
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature (1988) 19.07
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol (1989) 7.01
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell (1981) 5.38
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
Functional analysis of the internal translation initiation site of foot-and-mouth disease virus. J Virol (1990) 3.08
Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J Virol (2000) 2.97
A cell cycle-dependent internal ribosome entry site. Mol Cell (2000) 2.91
A cell cycle-dependent protein serves as a template-specific translation initiation factor. Genes Dev (2000) 2.84
Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A (1996) 2.71
Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14
Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol (1999) 2.11
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
In vitro reassembly of vesicular stomatitis virus skeletons. J Virol (1982) 2.03
The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol (2000) 1.89
Vesicular stomatitis. Vet J (1999) 1.73
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58
Picornavirus RNA translation: roles for cellular proteins. Trends Microbiol (2000) 1.53
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53
Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog (2009) 1.47
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 1.38
Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci (1998) 1.37
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27
Protein synthesis in eukaryotes: the growing biological relevance of cap-independent translation initiation. Biol Res (2005) 1.24
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J Virol (2006) 1.19
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Molecular and cellular aspects of rhabdovirus entry. Viruses (2012) 1.12
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol (2011) 1.06
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene (2006) 0.99
Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther (2012) 0.95
Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res (2008) 0.92
Interferon response and viral evasion by members of the family rhabdoviridae. Viruses (2009) 0.92
Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int J Cancer (2005) 0.90
Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model. J Neurosurg (2004) 0.87
Attenuation of rabies virus replication and virulence by picornavirus internal ribosome entry site elements. J Virol (2008) 0.85
Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements. J Virol (2006) 0.84
Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J Orthop Res (2010) 0.84
Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl) (2012) 0.83
Comparative neurovirulence of selected vesicular stomatitis virus temperature-sensitive mutants of complementation groups II and III. Infect Immun (1981) 0.82
Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. Hum Gene Ther (2011) 0.81
Antiviral activity of interferon in rats and the effect of immune suppression. J Gen Virol (1984) 0.79
Polykaryocytosis induced by vesicular stomatitis virus infection in BHK-21 cells. Arch Virol (1975) 0.79
Vesicular stomatitis virus-infected cells fuse when the intracellular pool of functional M protein is reduced in the presence of G protein. J Virol (1985) 0.76
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer (2006) 2.00
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80
Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A (2003) 1.70
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res (2002) 1.57
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res (2009) 1.48
Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res (2006) 1.47
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood (2011) 1.46
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol (2006) 1.42
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (2006) 1.40
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res (2006) 1.40
Antibody-targeted cell fusion. Nat Biotechnol (2004) 1.39
Diversity arrays technology (DArT) for pan-genomic evolutionary studies of non-model organisms. PLoS One (2008) 1.35
Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol (2006) 1.35
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther (2007) 1.32
Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood (2002) 1.32
In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol (2006) 1.30
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther (2010) 1.29
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood (2002) 1.27
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
MicroRNAs and the regulation of vector tropism. Mol Ther (2008) 1.25
Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood (2008) 1.25
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther (2007) 1.23
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat (2006) 1.21
Molecular phylogeny of the palm genus Chamaedorea, based on the low-copy nuclear genes PRK and RPB2. Mol Phylogenet Evol (2005) 1.19
Mathematical modeling of cancer radiovirotherapy. Math Biosci (2005) 1.19
Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol (2008) 1.19
Reengineering paramyxovirus tropism. Virology (2004) 1.18
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther (2012) 1.18
In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem (2003) 1.17
Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther (2008) 1.17
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood (2009) 1.16
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Genetically targeted radiotherapy for multiple myeloma. Blood (2003) 1.15
Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res (2007) 1.15
Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol (2010) 1.14
Assessing the use of the mitochondrial cox1 marker for use in DNA barcoding of red algae (Rhodophyta). Am J Bot (2006) 1.14
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 1.14
Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol (2009) 1.13
Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol (2010) 1.13